A team from Harvard and Dana-Farber has launched a Phase I clinical trial of a therapeutic melanoma vaccine designed to reprogram a patient’s immune system to destroy tumors. The vaccine consists of a small disk-like, biodegradable sponge that’s infused with signaling molecules and components of the patient’s tumor.
The disk-shaped, biodegradable sponge contains growth factors and components of each patient’s tumors. Researchers at the Wyss Institute and clinicians at Dana-Farber Cancer Institute hope that when it’s implanted under the patient’s skin, it will spur the immune system to attack and destroy tumors.
Read Cross-Disciplinary Team From Harvard and Dana-Farber Brings Novel Therapeutic Cancer Vaccine to Human Clinical Trials
Wyss Institute, 6 Sep. 2013
Related: Novel Therapeutic Cancer Vaccine Goes to Human Clinical Trials, Science Daily, 6 Sep. 2013